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Abstract After its first introduction in 2002, transcath-
eter aortic valve implantation (TAVI) has continuously
gained more foothold for the treatment of severe aortic
stenosis and is nowadays a viable treatment option for
inoperable patients or patients at high risk for conven-
tional surgical aortic valve replacement. Although ideal-
ly carried out in a so-called hybrid room, incorporating
both the strict hygiene and advanced life support possi-
bilities of the operating theatre and the imaging and
percutaneous arsenal of the catheterisation suite, in most
centres TAVI is at present performed in the catheter-
isation laboratory. This may raise concern about an
increased risk of infection, since there the criteria that
are applied regarding disinfection and sterilisation are
not as stringent as those of the operating theatre. There-
fore, we retrospectively assessed the number of infective
complications in patients undergoing TAVI in the cath-
eterisation lab of our institution. Eleven out of 73
patients developed a postprocedural infection, one of
which could be attributed to the procedure itself, being
superinfection of a surgical groin cut-down. Our con-
clusion is that percutaneous aortic valve implantation in
a catheterisation laboratory is not associated with an
increased risk of infective complications.
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Introduction
The treatment of aortic stenosis has been revolutionised by the
introduction of percutaneously insertable valve prostheses,
which have been demonstrated to be a viable treatment option
for inoperable patients or patients at high risk for conventional
surgical valve replacement [1, 2]. Two CE approved trans-
catheter bio-prosthetic aortic valves (the Edwards Sapien bal-
loon expandable valve (Edwards Lifescience, Inc., Irvine, CA,
USA) and the Medtronic self-expandable CoreValve (Med-
tronic CV, Luxembourg)) are currently on the market, which
can be implanted via a transfemoral (suitable for both types of
valves), transapical (Edwards valve only), subclavian (Med-
tronic CoreValve only) or, as recently reported, direct trans-
aortic approach [3] during a transcatheter aortic valve
implantation (TAVI). The decision whether a patient is treated
with a percutaneous or surgical valve should be discussed and
made in the heart team [4], a multidisciplinary meeting where
invasive and non-invasive cardiologists, cardiac surgeons and
ideally representatives from other disciplines involved such as
an anaesthesiologist and/or geriatrician, discuss the optimal
strategy to come to a patient-tailored therapy. At present, it is
generally accepted that surgical valve replacement still repre-
sents the gold standard for degenerated aortic valve stenosis,
whereas TAVI should be restricted to those patients too ill to be
operated on. Nevertheless, expectations are that in the foresee-
able future, if early benefit of TAVI is confirmed during long-
term follow-up, percutaneous valve treatment will become
available for a progressively broader patient population, includ-
ing low-risk surgical patients. This shift from surgical to trans-
catheter valve implantation not only entails a shift from the
cardiac surgeon to the interventional cardiologist as the primary
operator, but also frequently implies a move from the operating
theatre to the catheterisation room. There may be concerns that
a non-surgical environment might imply less stringent hygienic
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and sterile precautions, thereby increasing the risk for
procedure-related and prosthesis infections, especially in this
highly vulnerable patient group. Remmelts et al. already dem-
onstrated that the incidence of infection of an implantable
cardioverter-defibrillator did not differ between implantation
in the operating room and implantation in the cardiac catheter-
isation laboratory [5]. In a similar manner, our aim was to
retrospectively evaluate the rate of infective complications of
any kind in patients undergoing percutaneous aortic valve
replacement in the catheterisation suite of our institution.
Methods
Data collection
Electronic patient records from patients undergoing trans-
femoral or transapical TAVI from August 2008 to July 2011
were systematically reviewed. The following data were col-
lected: patient characteristics, comorbidities and cardiac his-
tory; procedural characteristics, including access site, type
of valve (brand and size) and performance of surgical groin
cut-down; occurrence of postoperative complications for up
to 30 days and 30-day survival. Complications were classi-
fied into eight different categories. For the aim of this study,
we specifically looked at infections, which were further
classified according to site of origin (as noted in the elec-
tronic patient record). Whenever possible, further informa-
tion about causal pathogen and treatment was assembled.
Aortic valve implantation
TAVI procedures were routinely performed by a team, con-
sisting of two interventional cardiologists, one cardiologist
specialised in echocardiography, one cardiac surgeon, one
anaesthetist and two specialised nurses. The procedure took
place in the catheterisation suite, which was cleaned the
evening before the TAVI procedure and only accessible for
persons wearing appropriate scrubs, masks, caps and, if stand-
ing at the operating table, gowns. At the beginning of the
procedure, meticulous hand washing and donning of sterile
gloves was done by each member of the operating team, and
the patient was prepped and draped in a sterile fashion. Forty-
five patients were treated via a transfemoral route, the remain-
ing 28 underwent a transapical approach according to standard
techniques as described earlier [6, 7]. In the early cohort of 27
patients, the right or left common femoral artery and vein were
surgically exposed at the beginning of the procedure in case
emergency cardiopulmonary bypass was needed.
With growing operator experience, this practice was
abandoned and a complete percutaneous access became
the gold standard in the subsequent 46 patients. All patients
were pre-treated with aspirin and clopidogrel and received
heparin during the procedure in order to maintain an acti-
vated clotting time above 250 ms. All patients received
antibiotic prophylaxis (first- or third-generation cephalospo-
rin or vancomycin). The size of the valve was chosen
according to echocardiographic estimate of aortic annulus
diameter and varied between 23 (24 patients), 26 (44
patients) and 29 mm (5 patients). All procedures were done
under general anaesthesia and with the aid of fluoroscopic
and transoesophageal echocardiographic guidance for accu-
rate valve deployment.
The stenotic valve was predilated with an undersized bal-
loon to facilitate valve implantation and subsequent valve
placement was accomplished during rapid pacing in the right
ventricle or epicardium. If necessary, additional post-dilation
was performed in case of relevant para-valvular regurgitation.
Results
Patients and procedures (Tables 1, 2)
Table 1 Patient characteristics and cardiac history
Clinical characteristics N (073)
Male sex 28 (38.3 %)
Age (years) 74.97 (±7.2)
Log EuroSCORE (%) 18 (±10.41)
Diabetes 22 (30.1 %)
COPD 14 (19.1 %)
Severe renal insufficiencya 14 (19.1 %)
Active malignancy 5 (6.8 %)
Peripheral vascular disease 20 (27.4 %)
Porcelain aorta 10 (13.7 %)
Previous stroke 13 (17.8 %)
Cardiac history
Previous myocardial infarction 20 (27.4 %)
Previous PCI 22 (30.1 %)
Previous CABG 15 (20.5 %)
Previous cardiac surgery other than CABG 3b (4.1 %)
Left ventricular ejection fraction <35 % 7 (9.6 %)
Moderate/severe mitral insufficiencyc 14 (19.2 %)
Pulmonary hypertensiond 26 (35.6 %)
CABG coronary artery bypass grafting; COPD chronic obstructive
pulmonary disease, PCI percutaneous coronary intervention
All data are presented as mean ± standard deviation or number
(percentage)
a Estimated glomerular filtration rate <30 ml/min/1.73 m2
b 2 pericardiectomies - 1 mitral valve plasty
c Echocardiographic estimate of ≥2/4 mitral regurgitation
d Echocardiographic measurement of pulmonary artery systolic pres-
sure >35 mmHg
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In a time span of almost 3 years, 73, predominantly
female, patients, received a percutaneous aortic valve. Mean
age and logistic EuroSCOREs were 75 (±7.2) and 18
(±10.41) respectively. Comorbidities included diabetes
(30.1 %), chronic obstructive pulmonary disease (19.1 %),
renal insufficiency (19.1 %), previous stroke (17.8 %), pe-
ripheral vascular disease (27.4 %), porcelain aorta (13.7 %)
and active malignancy (6.8 %). Seven patients (9.6 %) had a
severely depressed left ventricular systolic function; signif-
icant mitral insufficiency was present in 14 patients (19.2 %)
and 26 (35.6 %) suffered from pulmonary hypertension.
Forty-five patients (61.6 %) were treated via the transfe-
moral approach, the remaining 28 (38.4 %) via trans-apical
access. One-month survival approached 85 %.
Procedural and infective complications (Tables 3, 4, 5)
Total number of complications was 49, which were clas-
sified into eight different categories. Vascular complications
(including groin haematoma requiring transfusion, pseudo-
aneurysm, aorto/ileo/femoral dissection or rupture) occurred
in 15 patients (20.6 %); in 2 patients (2.7 %), the deployed
valve dislocated and migrated, necessitating emergent sur-
gery; incidence of transient ischaemic attack and stroke was
5.5 % (4 patients); tamponade (probably caused by perfora-
tion of the right ventricle by the temporary pacing wire) and
major non-access site bleeding (haemothorax) each occurred
in one patient; 2 patients suffered from contrast nephropathy
(none requiring dialysis); 13 patients (17.8 %) had postpro-
cedural rhythm disturbances (atrial fibrillation, severe bra-
dycardia or high-grade atrioventricular block compelling
pacemaker placement).
Eleven cases of infection were diagnosed during hospital
stay, including 5 of the urinary tract, 3 bronchopulmonary
infections, 1 in the groin and 2 infections of unknown cause.
Microbiology data were reviewed, but a pathogen could
only be isolated and identified (Acinetobacter) in the patient
with the infected groin. All patients were (empirically) trea-
ted with broad-spectrum antibiotics; 9 patients had a good
outcome, while 2 patients died. The first patient suffered
from overwhelming sepsis due to bilateral pneumonia (con-
firmed at obduction) and died 2 days after TAVI, while the
second patient, who had been treated for a urinary tract
infection, suddenly died 23 days post-TAVI. No autopsy
was performed in the last case.
Discussion
Since the emergence of percutaneous valves, high-risk
patients with degenerated aortic valve stenosis can be of-
fered a less invasive alternative instead of conventional
surgical valve replacement. Via the femoral, apical,
Table 2 Procedural details and 1-month survival rate
Procedural characteristics
TF/TA 45/28 (61.6/38.4 %)
Edwards/CoreValve 67/6 (91.7/8.2 %)
Valve size 23/26/29 24/44/5 (32.9/60.3/6.8 %)
Surgical groin exposition 27 (37 %)
Outcome
1-month survival 62 (84.93 %)
TF/TA transapical/transfemoral
All data are presented as number (percentage)
Table 3 Incidence of
periprocedural
complications





Vascular 15 (20.6 %)
Valve dislocation 2 (2.7 %)
TIA or stroke 4 (5.5 %)
Infective 11(15.1 %)
Rhythm 13 (17.8 %)
Tamponade 1 (1.4 %)
Contrast nephropathy 2 (2.7 %)
Non-access site bleeding 1 (1.3 %)
Table 4 Incidence of
infective complications





Groin 1 (1.4 %)
UTI 5 (6.8 %)
Bronchopulmonary 3 (4.1 %)
Unknown 2 (2.7 %)
Table 5 Characteristics of patients with infective complications




1 UTI Transapical 1.8 Yes
2 UTI Transfemoral 12.08 Yes
3 Unknown origin Transfemoral 13.44 Yes
4 UTI Transapical 29.02 Yes
5 Pneumonia Transfemoral 36.78 No
6 UTI Transapical 15.6 No
7 Pneumonia Transapical 11.66 Yes
8 UTI Transfemoral 11 Yes
9 Bronchitis Transapical 21.95 Yes
10 Unknown origin Transfemoral 10.88 Yes
11 Groin Transapical 16 Yes
UTI urinary tract infection
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subclavian or direct aortic approach, a transcatheter aortic
bioprosthesis can be introduced, positioned and deployed
inside the native valve, which itself is oppressed against the
aortic wall. After its introduction in 2002 [8], the number of
TAVI procedures has grown exponentially and its number
will continue to increase, as more and more evidence
becomes available supporting the benefit of a percutaneous
approach in high-risk patients, not only compared with
medical therapy, which entails a dismal prognosis in symp-
tomatic aortic stenosis, but even when compared with the
gold standard of surgery. Indications and suitability for TAVI
should be formally discussed in the heart team, where surgery
is balanced against this new transcatheter technique, for which
long-term results regarding valve patency and patient survival
are still lacking. Numerous factors (e.g. patient comorbidities
and ‘frailty’, preferred access site, aortic annulus dimensions
and calcification) should be taken into account to reach an
optimal, individualised treatment plan.
In most centres, the insertion of a percutaneous aortic
valve is carried out jointly by the cardiologist and cardiac
surgeon, the first being traditionally skilled in catheter
manipulations, the latter in creating access for apical or
direct aortic approach. Ideally, TAVI procedures should be
performed in a ‘hybrid’ room, an integration of cath lab and
operating theatre where the traditional diagnostic functions
of the cath lab are combined with the surgical functions of
an operating room. However, at present, many hospitals that
have started doing TAVI procedures do not have a hybrid
lab, and therefore, TAVI procedures are often performed in
the catheterisation lab.
Although strict sterile working conditions are pursued,
high-efficiency particulate air filtered laminar airflow is
absent in most cath labs and criteria regarding air control,
room facilities and specific staff education are not as stringent
as those of the operating theatre. Since this may increase the
risk for procedure-related infection, we retrospectively evalu-
ated the number of infections in 73 patients who underwent
TAVI in our centre during a time span of almost three years.
We found 11 cases of infection, only one of which was
directly related to the TAVI procedure, being superinfection
of a surgically cut-down groin. This patient stemmed from the
early patient cohort, during which the groin was ‘per protocol’
surgically exposed, in the event that emergent cardiopulmonary
bypass was needed. Parallel with growing experience, this
practice has been abandoned for an exclusive percutaneous
approach. The 10 other cases of infections that were seen
postprocedurally were of pulmonary, urinary or unknown ori-
gin, which can be anticipated in a high-risk patient population
undergoing invasive procedures under general anaesthesia,
whether these are performed in a catheterisation suite or oper-
ating theatre. Patients were treated with broad-spectrum anti-
biotics and had a favourable 1-month outcome, except for one
patient who died of overwhelming sepsis due to bilateral
pneumonia and another who suddenly succumbed 23 days
postprocedure due to an unknown cause. It is reassuring that
no cases of early prosthetic infection occurred in our patients. In
the PARTNER (cohort B) trial (2), which is the largest rando-
mised trial comparing TAVI and surgical valve replacement in
high-risk patients, the location where TAVI was performed was
not mentioned, nor was periprocedural infection specified as an
endpoint. However, the incidence of endocarditis is reported,
with a low incidence of prosthesis infection at 30 days (0 in
TAVI patients and one in the surgical cohort) and one year (2 in
the TAVI group, compared with 3 surgically implanted valve
infections). Recently, we started to perform transfemoral TAVI
using conscious sedation (thus avoiding intubation) and utilis-
ing intravascular instead of transoesophageal ultrasound guid-
ance, hoping that this practice will result in improved and
quicker patient recovery and thus less infection.
Conclusion
In this single-centre registry the incidence of periprocedural
infections complicating TAVI was low and only one case
was directly related to the procedure itself, being superin-
fection of a surgically exposed groin. Although our study
was observational and underpowered to detect the potential
impact of cath lab versus operating theatre on infectious
complications, it hints that percutaneous aortic valve im-
plantation can be performed in a catheterisation laboratory
without apparent increased risk of infective complications.
Larger studies are needed to confirm this.
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